Literature DB >> 9883811

Severe tumor lysis syndrome following splenic irradiation.

T Schifter1, A Cohen, U H Lewinski.   

Abstract

A 72-year-old man suffering from non-Hodgkin's lymphoma is described. After failing to respond to chlorambucil-prednisone regimen for three months, he was treated by splenic irradiation (total dose 500 cGY) in 10 consecutive daily doses. Two days after the last irradiation, the patient developed acute tumor lysis syndrome (TLS) with extreme blood levels of uric acid (33.7 mg/dl), phosphorus (13.7 mg/dl), potassium (6.08 mEq/l), and calcium (6.8 mg/dl). It should be remembered that the acute TLS, which usually occurs following chemotherapy, can also be radiation-induced.

Entities:  

Mesh:

Year:  1999        PMID: 9883811     DOI: 10.1002/(sici)1096-8652(199901)60:1<75::aid-ajh14>3.0.co;2-2

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  3 in total

1.  Development and translational imaging of a TP53 porcine tumorigenesis model.

Authors:  Jessica C Sieren; David K Meyerholz; Xiao-Jun Wang; Bryan T Davis; John D Newell; Emily Hammond; Judy A Rohret; Frank A Rohret; Jason T Struzynski; J Adam Goeken; Paul W Naumann; Mariah R Leidinger; Agshin Taghiyev; Richard Van Rheeden; Jussara Hagen; Benjamin W Darbro; Dawn E Quelle; Christopher S Rogers
Journal:  J Clin Invest       Date:  2014-08-08       Impact factor: 14.808

2.  Cytokine release syndrome and tumor lysis syndrome in a multiple myeloma patient treated with palliative radiotherapy: A case report and review of the literature.

Authors:  Axel Cailleteau; Cyrille Touzeau; Bastien Jamet; Valentine Guimas; Emmanuel Jouglar; Stéphane Supiot
Journal:  Clin Transl Radiat Oncol       Date:  2021-11-12

3.  Tumor lysis syndrome during radiotherapy for prostate cancer with bone and bone marrow metastases without visceral metastasis.

Authors:  Muhammet Ali Kaplan; Mehmet Kucukoner; Gulistan Alpagat; Abdurrahman Isikdogan
Journal:  Ann Saudi Med       Date:  2012 May-Jun       Impact factor: 1.526

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.